EUVIMEDEUVIMED entdecken
Crossref

Daratumumab (Darzalex SC)

CDA-AMC

Canadian Journal of Health Technologies · 08.05.2026 · 6 (5)

DOI: 10.51731/cjht.2026.1436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 08.05.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses daratumumab (Darzalex SC), 1800 mg/15 mL (120 mg/mL) single-dose vial solution for subcutaneous injection. Indication: Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.

Zitieren

APA

CDA-AMC (2026). Daratumumab (Darzalex SC). Canadian Journal of Health Technologies, 6(5). https://doi.org/10.51731/cjht.2026.1436

Vancouver

CDA-AMC. Daratumumab (Darzalex SC). Canadian Journal of Health Technologies. 2026;6(5). doi:10.51731/cjht.2026.1436

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Daratumumab (Darzalex SC)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {5},
  doi = {10.51731/cjht.2026.1436}
}
Kostenlos starten →